Transparency Market Research

Increased Awareness and Financial Support for Mental Health and Substance Abuse Treatment Drives Substance Abuse Treatment Market

Substance Abuse Treatment Market - Industry Analysis and Forecast upto 2023


Albany, NY -- (SBWIRE) -- 11/17/2016 -- There has been an increase in the use and abuse of the substances such as alcohol, drugs, and cigarettes. Substance abuse is defined as harmful use of these substances in order to alter the mood. Generally, substance abuse is referred to the use of illegal drugs as these are potentially addictive and can pose negative health effects. However, alcohol, inhalants, solvents and even coffee can be abused. Hence, almost any substance can be used to a harmful extent and can be abused. Substance abuse results in health deterioration irrespective of addiction. Chaotic home environment, genetic risks, poor social coping skills and inappropriate behavior are some of the factors that may cause substance abuse. Early recognition of substance abuse symptoms can increase the chances of successful treatment.

Obtain the Future Market Projections for Substance Abuse Treatment at:

Aggressiveness, irritability and forgetfulness constitute substance abuse symptoms. Doctors recommend community resources for the patients willing to quit the substance abuse. During this process doctors may also prescribe certain medications that help control the cravings and manage the medical complications resulting from the substance abuse. As a part of education the patients are recommended to seek immediate medical care if they experience these symptoms. Currently, with the increasing use of illicit drugs, leading to increased number of deaths and healthcare costs. For instance, in the United States, illicit drug prescription and alcohol abuse resulted in around more than 90,000 deaths while tobacco abuse results in around 480,000 deaths annually. Furthermore, management of increasing addiction and abuse to nicotine, alcohol and illicit prescription drugs costs around USD 700 billion for the Americans every year.

Several research studies identified that combination of behavioral therapy along with medications ensures best mode of treating the patients. This is necessary as long term use of drugs alters the brain function and enhances the compulsions to use the drugs. Hence, prevention of relapse is one of the most important components of substance abuse treatment. Behavioral therapy enables the patient to cope up with the drug cravings and avoid relapse. Medications such as Methadone and nicotine patches assist in controlling the withdrawal symptoms and drug cravings. Medical treatment is necessary as drug users are observed to have an underlying medical disorder which must be treated along with the drug abuse treatment.

The market for substance abuse therapeutics can be segmented into alcohol, nicotine dependence therapeutics and drug abuse therapeutics. For instance, Chantix (vareniciline) and zyban represents the medications prescribed against nicotine addiction. In addition, Vivitrol (naltrexone), Campral (acamprosate calcium) and disulfrum are some of the drugs recommended for the patients suffering from alcohol dependence. Cocaine and opioid abuse are some of the drug abuse therapeutics. Other factors such as annual cost of the treatment and regulatory policies govern the market growth. Geographically, developed economies such as the U.S., the U.K., Japan, Germany, France, Spain and others exhibit high number of substance abuse patients as compared to developing economies such as China and India.

Read the Current Industrial Structure for Substance Abuse Treatment at:

The factors such as increased awareness and financial support for mental health and substance abuse treatment along with increasing substance abuse illness will drive the market growth. Furthermore, this factor favors the growth of mental and substance abuse centers. On the other hand factors such as no control over the addiction and lack of willingness to seek treatment for the substance abuse might restrain the market growth. Teva Pharmaceutical Industries, ltd., GlaxoSmithKline plc, Alkermes plc, Reckitt Benckiser Pharmaceuticals, Inc. and Pfizer, Inc. are some of the companies operating in this market.